Insider Buying: InMed Pharmaceuticals (NASDAQ:INM) Major Shareholder Acquires $49,400.00 in Stock

Posted by Brian Himes on Jun 13th, 2026

InMed Pharmaceuticals Inc. (NASDAQ:INM – Get Free Report) major shareholder Vivo Opportunity, Llc purchased 32,500 shares of the stock in a transaction dated Monday, June 8th. The shares were acquired at an average cost of $1.52 per share, for a total transaction of $49,400.00. Following the completion of the acquisition, the insider directly owned 718,444 shares of the company’s stock, valued at approximately $1,092,034.88. This trade represents a 4.74% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Vivo Opportunity, Llc also recently made the following trade(s):

On Friday, June 5th, Vivo Opportunity, Llc purchased 55,011 shares of InMed Pharmaceuticals stock. The shares were acquired at an average cost of $1.57 per share, for a total transaction of $86,367.27.
On Thursday, June 4th, Vivo Opportunity, Llc bought 6,743 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.57 per share, with a total value of $10,586.51.
On Wednesday, June 3rd, Vivo Opportunity, Llc bought 7,783 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.55 per share, with a total value of $12,063.65.
On Tuesday, June 2nd, Vivo Opportunity, Llc bought 22,848 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.52 per share, with a total value of $34,728.96.
On Monday, June 1st, Vivo Opportunity, Llc bought 16,336 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.55 per share, with a total value of $25,320.80.
On Friday, May 29th, Vivo Opportunity, Llc bought 17,796 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.57 per share, with a total value of $27,939.72.
On Thursday, May 21st, Vivo Opportunity, Llc bought 34,000 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.69 per share, with a total value of $57,460.00.
On Wednesday, May 20th, Vivo Opportunity, Llc bought 56,210 shares of InMed Pharmaceuticals stock. The shares were purchased at an average cost of $1.56 per share, with a total value of $87,687.60.

InMed Pharmaceuticals Stock Down 4.4%

Shares of INM stock opened at $1.51 on Friday. The stock has a 50-day simple moving average of $1.04 and a 200 day simple moving average of $1.04. InMed Pharmaceuticals Inc. has a fifty-two week low of $0.58 and a fifty-two week high of $5.50. The stock has a market capitalization of $5.00 million, a P/E ratio of -0.52 and a beta of 0.98.

InMed Pharmaceuticals (NASDAQ:INM – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.69) earnings per share for the quarter, beating the consensus estimate of ($94.44) by $93.75. InMed Pharmaceuticals had a negative return on equity of 80.85% and a negative net margin of 132.87%.

Hedge Funds Weigh In On InMed Pharmaceuticals

A hedge fund recently bought a new stake in InMed Pharmaceuticals stock. Virtu Financial LLC purchased a new stake in InMed Pharmaceuticals Inc. (NASDAQ:INM – Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 20,369 shares of the company’s stock, valued at approximately $45,000. Virtu Financial LLC owned 0.73% of InMed Pharmaceuticals as of its most recent SEC filing. 20.12% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of InMed Pharmaceuticals in a research note on Tuesday, April 21st. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company currently has an average rating of “Sell”.

Check Out Our Latest Research Report on INM

About InMed Pharmaceuticals

(Get Free Report)

InMed Pharmaceuticals is a clinical-stage biopharmaceutical company headquartered in Vancouver, British Columbia, that is dedicated to the discovery and development of novel therapeutics derived from cannabinoids. Leveraging a proprietary drug discovery engine, the company works to identify, design and optimize cannabinoid-based molecules with the goal of addressing diseases that have significant unmet medical needs. InMed’s integrated business model combines research, development and manufacturing capabilities under one roof to streamline the progression of promising assets from preclinical studies into human trials.

The company’s pipeline features multiple lead programs targeting both neurological and dermatological disorders.